Navigation Links
IDEXX Laboratories Elects Joseph Vumbacco as Director
Date:3/2/2010

WESTBROOK, Maine, March 2 /PRNewswire-FirstCall/ -- IDEXX Laboratories, Inc. (Nasdaq: IDXX), announced today that Mr. Joseph V. Vumbacco has been elected to its Board of Directors. Mr. Vumbacco served as Chief Executive Officer of Health Management Associates, Inc. (HMA), a premier operator of acute care hospitals, from 2001 until June 2007, and as Vice Chairman of HMA from June 2007 until his retirement in December 2007.  Before joining HMA, Mr. Vumbacco had a nearly 15-year career with The Turner Corporation, a publicly-traded construction and real estate company, where he served most recently as Executive Vice President. Mr. Vumbacco also served as Senior Vice President and General Counsel at The F&M Schaefer Corporation, a publicly-traded brewing company, and earlier as an attorney at the Wall Street firm of Mudge Rose Guthrie & Alexander where he specialized in corporate and securities law.

"We are very fortunate to have Joseph Vumbacco join our Board of Directors," said Jonathan W. Ayers, Chairman and Chief Executive Officer of IDEXX Laboratories. "Joe brings a wealth of executive leadership experience to our Board, including experience managing HMA during a period of significant and sustained revenue growth. I believe that Joe's experience as a chief executive, as well as his experience in other executive leadership positions, will be a valuable addition to our Board."

About IDEXX Laboratories

IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,800 people and offers products to customers in over 100 countries.

Contact: Merilee Raines, Chief Financial Officer, 1-207-556-8155

SOURCE IDEXX Laboratories, Inc.

Back to top

RELATED LINKS
http://www.idexx.com

'/>"/>

SOURCE IDEXX Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. IDEXX Laboratories Announces Second Quarter Results
2. IDEXX Laboratories to Release 2009 Second Quarter Financial Results
3. IDEXX Laboratories to Present at William Blair 29th Annual Growth Stock Conference
4. IDEXX Laboratories Announces First Quarter Results
5. IDEXX Laboratories to Release 2009 First Quarter Financial Results
6. IDEXX Laboratories Announces Fourth Quarter and Full Year Results
7. IDEXX Laboratories to Release 2008 Fourth Quarter and Full-Year Financial Results
8. IDEXX Laboratories Names William Brown Corporate Vice President
9. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
10. IDEXX Laboratories to Release 2008 First Quarter Financial Results
11. IDEXX Laboratories Announces Increase in Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... One ... regular changing of the securement tape is painful for her. "This is why the ... to patients’ heads," she said. , They then created a prototype of the patent-pending ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic and ... website, which launched October 17, 2016, features comprehensive information regarding a wide range ... Visitors and patients can discover the latest clinical dermatology treatments for medical skin ...
(Date:12/7/2016)... ... , ... The medical profession is well aware that heart attacks do indeed ... heart attacks among 138,602 people recorded a 35% higher number of heart attacks in ... of course–no time of year is a good time for a heart attack! In ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: ... trial, not a one hour a week showing of hands. “The Road To Restoration” ... begins, “Perhaps you are familiar with the brass ring that you could reach out ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 2016   Arena Pharmaceuticals, Inc. (NASDAQ: ... enrollment in the ralinepag phase 2 trial.  Ralinepag is ... pathway for the treatment of pulmonary arterial hypertension (PAH). ... "This marks an important step in the ... focus on our pipeline," said Amit Munshi , ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 According to ... in more than one-third (38%) of patients with non-small cell ... epidermal growth factor receptor (EGFR) genetic mutation status. The findings ... ( LBA ID #6067 #P3.02b ) at the ... Vienna, Austria . The survey results revealed ...
(Date:12/7/2016)... 7,2016  Based on its recent analysis ... & Sullivan recognizes Nemaura Pharma Limited with ... for Enabling Technology Leadership. Nemaura Pharma,s transdermal ... traditional drug delivery technologies, especially in delivering ... delivery technologies, Memspatch and Micropatch respectively, facilitate ...
Breaking Medicine Technology: